You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

72 Results
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Adjuvant
Dec 2017
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant
Aug 2018
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Palliative
May 2019
Regimen
Cancer Type:
Endocrine, 
Adrenal
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Curative
Sep 2019
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Jan 2023
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Apr 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Nivolumab - Neoadjuvant Treatment for Non-Small Cell Lung Cancer
Jul 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer
New Drug Funding Program
    Nivolumab plus Ipilimumab - In Combination with Platinum Doublet Chemotherapy for First Line Metastatic or Recurrent Non-Small Cell Lung Cancer
Aug 2022

Pages